Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
Identifieur interne : 004132 ( PubMed/Corpus ); précédent : 004131; suivant : 004133Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
Auteurs : P. Barbanti ; G. Fabbrini ; A. Ricci ; R. Cerbo ; E. Bronzetti ; B. Caronti ; C. Calderaro ; L. Felici ; F. Stocchi ; G. Meco ; F. Amenta ; G L LenziSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1999.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Binding, Competitive (physiology), Brain (pathology), Cell Count, Dopamine Agonists (pharmacokinetics), Female, Humans, Levodopa (therapeutic use), Lymphocytes (metabolism), Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Radioligand Assay, Receptors, Dopamine (metabolism), Sensitivity and Specificity, Treatment Outcome.
- MESH :
- chemical , metabolism : Receptors, Dopamine.
- chemical , pharmacokinetics : Dopamine Agonists.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Lymphocytes, Parkinson Disease.
- pathology : Brain.
- physiology : Binding, Competitive.
- Aged, Cell Count, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Radioligand Assay, Sensitivity and Specificity, Treatment Outcome.
Abstract
Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple-system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH-DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1-like (p <0.001) and D2-like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH-DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty-five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1-like (p <0.001) and D2-like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1-like and D2-like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.
PubMed: 10495037
Links to Exploration step
pubmed:10495037Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.</title><author><name sortKey="Barbanti, P" sort="Barbanti, P" uniqKey="Barbanti P" first="P" last="Barbanti">P. Barbanti</name><affiliation><nlm:affiliation>Department of Neurosciences, University La Sapienza, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fabbrini, G" sort="Fabbrini, G" uniqKey="Fabbrini G" first="G" last="Fabbrini">G. Fabbrini</name></author><author><name sortKey="Ricci, A" sort="Ricci, A" uniqKey="Ricci A" first="A" last="Ricci">A. Ricci</name></author><author><name sortKey="Cerbo, R" sort="Cerbo, R" uniqKey="Cerbo R" first="R" last="Cerbo">R. Cerbo</name></author><author><name sortKey="Bronzetti, E" sort="Bronzetti, E" uniqKey="Bronzetti E" first="E" last="Bronzetti">E. Bronzetti</name></author><author><name sortKey="Caronti, B" sort="Caronti, B" uniqKey="Caronti B" first="B" last="Caronti">B. Caronti</name></author><author><name sortKey="Calderaro, C" sort="Calderaro, C" uniqKey="Calderaro C" first="C" last="Calderaro">C. Calderaro</name></author><author><name sortKey="Felici, L" sort="Felici, L" uniqKey="Felici L" first="L" last="Felici">L. Felici</name></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F" last="Stocchi">F. Stocchi</name></author><author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G" last="Meco">G. Meco</name></author><author><name sortKey="Amenta, F" sort="Amenta, F" uniqKey="Amenta F" first="F" last="Amenta">F. Amenta</name></author><author><name sortKey="Lenzi, G L" sort="Lenzi, G L" uniqKey="Lenzi G" first="G L" last="Lenzi">G L Lenzi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10495037</idno><idno type="pmid">10495037</idno><idno type="wicri:Area/PubMed/Corpus">004132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.</title><author><name sortKey="Barbanti, P" sort="Barbanti, P" uniqKey="Barbanti P" first="P" last="Barbanti">P. Barbanti</name><affiliation><nlm:affiliation>Department of Neurosciences, University La Sapienza, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fabbrini, G" sort="Fabbrini, G" uniqKey="Fabbrini G" first="G" last="Fabbrini">G. Fabbrini</name></author><author><name sortKey="Ricci, A" sort="Ricci, A" uniqKey="Ricci A" first="A" last="Ricci">A. Ricci</name></author><author><name sortKey="Cerbo, R" sort="Cerbo, R" uniqKey="Cerbo R" first="R" last="Cerbo">R. Cerbo</name></author><author><name sortKey="Bronzetti, E" sort="Bronzetti, E" uniqKey="Bronzetti E" first="E" last="Bronzetti">E. Bronzetti</name></author><author><name sortKey="Caronti, B" sort="Caronti, B" uniqKey="Caronti B" first="B" last="Caronti">B. Caronti</name></author><author><name sortKey="Calderaro, C" sort="Calderaro, C" uniqKey="Calderaro C" first="C" last="Calderaro">C. Calderaro</name></author><author><name sortKey="Felici, L" sort="Felici, L" uniqKey="Felici L" first="L" last="Felici">L. Felici</name></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F" last="Stocchi">F. Stocchi</name></author><author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G" last="Meco">G. Meco</name></author><author><name sortKey="Amenta, F" sort="Amenta, F" uniqKey="Amenta F" first="F" last="Amenta">F. Amenta</name></author><author><name sortKey="Lenzi, G L" sort="Lenzi, G L" uniqKey="Lenzi G" first="G L" last="Lenzi">G L Lenzi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Binding, Competitive (physiology)</term><term>Brain (pathology)</term><term>Cell Count</term><term>Dopamine Agonists (pharmacokinetics)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Lymphocytes (metabolism)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Radioligand Assay</term><term>Receptors, Dopamine (metabolism)</term><term>Sensitivity and Specificity</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphocytes</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Binding, Competitive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cell Count</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Radioligand Assay</term><term>Sensitivity and Specificity</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple-system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH-DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1-like (p <0.001) and D2-like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH-DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty-five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1-like (p <0.001) and D2-like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1-like and D2-like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10495037</PMID><DateCreated><Year>1999</Year><Month>11</Month><Day>10</Day></DateCreated><DateCompleted><Year>1999</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>1999</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>764-71</MedlinePgn></Pagination><Abstract><AbstractText>Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple-system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH-DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1-like (p <0.001) and D2-like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH-DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty-five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1-like (p <0.001) and D2-like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1-like and D2-like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbanti</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University La Sapienza, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrini</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cerbo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bronzetti</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Caronti</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Calderaro</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Felici</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stocchi</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Meco</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Amenta</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001667">Binding, Competitive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002452">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011869">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>9</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>9</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10495037</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10495037
|texte= Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10495037" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |